Beverly Long, MD
Gynecologic Oncology · Sarasota, FLNPI 1932497245
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Merck at 53.5% of the total. Reporting peaked in 2019 at $1,793 and has fallen 80.9% since, to $342 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in FL, where the typical reported total is $2,602.
Across 19 payments — averaging $144.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Intuitive Surgical$605
- AstraZeneca$201
- E.r. Squibb & Sons, L.L.C.$137
- Dilon Technologies, Inc.$123
- Tesaro, Inc.$120
- plus $95 from 2 others
Across 79 payments — averaging $23,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.5M
- Alkermes, Inc.$180K
- AbbVie$136K
- Genmab U.S., Inc.$44K
- Immunogen, Inc.$28K
What the payments were for
- Travel & lodging$1,57957%
- Food & beverage$1,17443%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $1,472 |
| Intuitive Surgical | 4 | $605 |
| AstraZeneca | 2 | $201 |
| E.r. Squibb & Sons, L.L.C. | 2 | $137 |
| Dilon Technologies, Inc. | 1 | $123 |
| Tesaro, Inc. | 1 | $120 |
| Baxter Healthcare | 1 | $82 |
| Stryker | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MK-7339$1,239
- Da Vinci Surgical System$456
- HemoBlast Bellows$123
- ZEJULA$120
- LYNPARZA$117
- KEYTRUDA$105
How this compares
$2,753 in reported general payments places this provider in the 50th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $5,512 |
| Estradiol | 28 | $1,898 |
| Clobetasol Propionate | 15 | $945 |
| Oxycodone Hcl | 32 | $111 |
| Ibuprofen | 17 | $41 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Sarasota
- Stacey SouthSarasota$20K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Ricardo EstapeMiami$457K
- Robert HollowayOrlando$432K
- Shelly SewardOrlando$349K
- Edward GrendysFort Myers$341K
- Jonathan BlackMiramar$329K
- Nathalie McKenzieOrlando$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.